Can LivaNova Succeed Where Others Have Failed in HF?

LivaNova continues to live up to the promise it made to shareholders that it would focus more on its neuromodulation and cardiac surgery businesses. Through the VITARIA neuromodulation technology, the London and Houston, TX-based firm is fulfilling that promise with one device and one fell swoop. “We clearly talk about ourselves as a company focused on the head and the heart,” Edward Andrle, LivaNova’s General Manager of Neuromodulation, told MD+DI. “What’s interesting about this therapy is that it is a neuromodulation therapy. But the indication that we’re treating is for heart failure.”  LivaNova said it was launching the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study. The study will enroll up to 800 patients. Please join us for MD&M Minneapolis on Oct. 31 and Nov. 1.  “Patients’ autonomic nervous system tend to get out of balance when they have heart failure,” Andrle said. “What we’re doing in essence with vagus nerve stimulation is trying to bring the sympathetic and parasympathetic systems back into balance.” The VITARIA System received CE mark in 2015 when it was owned by Cyberonics, a comp...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news